Art. -Nr.: HY-W011243

11alpha-Hydroxyprogesterone

Name: 11alpha-Hydroxyprogesterone
Brand: MedChemExpress
SKU: HY-W011243
Price: 50.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Kundenbewertung

Based on 1 Customer Validation

11alpha-Hydroxyprogesterone is a naturally occurring steroid hormone and an 11β-hydroxysteroid dehydrogenase (11β-HSD) inhibitor. 11alpha-Hydroxyprogesterone decreases FAK protein expression and regulates epithelial-mesenchymal transition, cell migration, and cell invasion. 11alpha-Hydroxyprogesterone exhibits antiandrogenic and blood pressure-regulating activities. 11alpha-Hydroxyprogesterone is used in the research of breast cancer and malaria.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.53%
CAS. Nr.: 80-75-1
Formel: C₂₁H₃₀O₃
Molecular Weight:330.46

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

11alpha-Hydroxyprogesterone Chemical Structure

CAS. Nr.: 80-75-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	0.4 μM Compound: 1b	Inhibition of human recombinant 11beta-HSD2 expressed in HEK293 cells assessed as inhibition of [1,2,6,7-3H]-cortisol to [3H]cortisone preincubated for 10 mins before substrate addition by scintillation counting Inhibition of human recombinant 11beta-HSD2 expressed in HEK293 cells assessed as inhibition of [1,2,6,7-3H]-cortisol to [3H]cortisone preincubated for 10 mins before substrate addition by scintillation counting	[PMID: 24074876]
HEK293	IC₅₀	0.63 μM Compound: 1b	Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as inhibition of [1,2,-3H]-cortisone to [3H]cortisol preincubated for 10 mins before substrate addition by scintillation counting Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as inhibition of [1,2,-3H]-cortisone to [3H]cortisol preincubated for 10 mins before substrate addition by scintillation counting	[PMID: 24074876]

In Vitro

Anti-cancerParasitic Infection

Anti-cancer

11alpha-Hydroxyprogesterone (11α-OHP) (1-10 µM; 24 h) inhibits the migration and invasion of MDA-MB-231 cells^[1].
In MDA-MB-231 cells, 11α-OHP (10 µM; 24 h) treatment directly increases E-cadherin levels and reduces vimentin expression^[1].
11α-OHP (1-10 µM; 24 h) does not exhibit cytotoxic or proliferative effects on MDA-MB-231 cells^[1].
11α-OHP treatment does not significantly alter E-cadherin or N-cadherin expression in MCF-7 cells^[1].

Parasitic Infection

11alpha-Hydroxyprogesterone is a high-affinity hit compound that binds to the active sites of both Plasmodium falciparum FabI and FabZ, with binding energies of −10.7 kcal/mol and −10.0 kcal/mol, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[1]

Cell Line:

MDA-MB-231
Concentration:

1 µM, 10 µM
Incubation Time:

24 h
Result:

Decreased the degree of migration by 13.2%.
Reduced transwell migration by 49.6% at 1 µM and 67.3% at 10 µM.
Decreased transwell invasion rate by 47.2% at 1 µM and 71.3% at 10 µM.

Western Blot Analysis^[1]

Cell Line:

MDA-MB-231
Concentration:

10 µM
Incubation Time:

24 h
Result:

Increased E-cadherin levels by 2.11-fold compared to control.
Decreased vimentin expression by 44.9% compared to control.

Cell Viability Assay^[1]

Cell Line:

MDA-MB-231
Concentration:

1 µM, 10 µM
Incubation Time:

24 h
Result:

Did not exhibit cytotoxic or proliferative effects.

In Vivo

Apoptosis

11alpha-Hydroxyprogesterone (11α-OHP) (60 mg/mouse; s.c.; over a 5-week period) does not affect primary tumor growth but significantly suppresses lung metastasis in the MMTV-PyMT breast cancer model by modulating EMT markers^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

FVB/N-Tg(MMTV-PyVT)634Mul/J (female, 10 weeks old)^[1]
Dosage:

60 mg/mouse
Administration:

s.c.; over a 5-week period
Result:

Did not significantly alter body weight or primary tumor growth.
Increased E-cadherin protein levels by 1.52-fold and claudin-1 levels by 1.51-fold in tumors.
Reduced vimentin levels by 34% in tumors.
Decreased FAK expression by 93.3% in tumors.
Reduced lung metastasis incidence by 15.5%.
Decreased FAK expression by 13% in lung tissues.
Increased E-cadherin and claudin-1 expression in lung tissues by 4.27-fold and 5.54-fold, respectively.

Related Protocols :

Chemical Information

CAS. Nr. 80-75-1
Appearance Solid
Molecular Weight 330.46
Formel C₂₁H₃₀O₃
Color White to off-white
SMILES

C[C@@]12[C@]3([H])[C@](CCC1=CC(CC2)=O)([H])[C@@]4([H])[C@](C[C@H]3O)([C@H](CC4)C(C)=O)C
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (302.61 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0261 mL

15.1304 mL

30.2609 mL

5 mM

0.6052 mL

3.0261 mL

6.0522 mL

10 mM

0.3026 mL

1.5130 mL

3.0261 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (294 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kim N, et al. 11α-hydroxyprogesterone dampens lung metastasis via EMT modulation in PyMT-induced breast cancer murine model. Lab Anim Res. 2025 Oct 14;41(1):26.

[2]. Kane NF, et al. Expression of the Fab enzymes (Fab I and Fab Z) from Plasmodium falciparum after exposure to Artemisia afra plant extracts and drugs screening. J Parasit Dis. 2023 Mar;47(1):46-58.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0261 mL	15.1304 mL	30.2608 mL	75.6521 mL
	5 mM	0.6052 mL	3.0261 mL	6.0522 mL	15.1304 mL
	10 mM	0.3026 mL	1.5130 mL	3.0261 mL	7.5652 mL
	15 mM	0.2017 mL	1.0087 mL	2.0174 mL	5.0435 mL
	20 mM	0.1513 mL	0.7565 mL	1.5130 mL	3.7826 mL
	25 mM	0.1210 mL	0.6052 mL	1.2104 mL	3.0261 mL
	30 mM	0.1009 mL	0.5043 mL	1.0087 mL	2.5217 mL
	40 mM	0.0757 mL	0.3783 mL	0.7565 mL	1.8913 mL
	50 mM	0.0605 mL	0.3026 mL	0.6052 mL	1.5130 mL
	60 mM	0.0504 mL	0.2522 mL	0.5043 mL	1.2609 mL
	80 mM	0.0378 mL	0.1891 mL	0.3783 mL	0.9457 mL
	100 mM	0.0303 mL	0.1513 mL	0.3026 mL	0.7565 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

11alpha-Hydroxyprogesterone